Poseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is Euphoric
The deal underscores Roche's interest in Poseida’s proprietary non-viral platform, which enables the development of allogeneic CAR-T therapies enriched with T stem cell memory cells.